bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
NASDAQ:BLUE
Price:
1.015 USD
-4.25%
Market Closed
Updated:
May 13, 2024
bluebird bio Inc
Selling, General & Administrative
|
bluebird bio Inc
Selling, General & Administrative Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
bluebird bio Inc
NASDAQ:BLUE
|
Selling, General & Administrative
-$149.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-29%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$12.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$6.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-12%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-23%
|
See Also
What is bluebird bio Inc's Selling, General & Administrative?
Selling, General & Administrative
-149.1m
USD
-149.1m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Selling, General & Administrative amounts to -149.1m USD.
What is bluebird bio Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-29%
-29%
Over the last year, the Selling, General & Administrative growth was 4%. The average annual Selling, General & Administrative growth rates for bluebird bio Inc have been 16% over the past three years , and -29% over the past ten years .
You don't have any saved screeners yet
